Drugs that contain Levetiracetam
1. Elepsia Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8535717 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(2 years from now) | |
| US8425938 | TRIPOINT | Pharmaceutical composition |
Feb, 2026
(2 years from now) | |
| US8163306 | TRIPOINT | Oral drug delivery system |
Sep, 2027
(3 years from now) | |
| US8470367 | TRIPOINT | Oral drug delivery system |
Oct, 2027
(3 years from now) | |
| US8431156 | TRIPOINT | Pharmaceutical composition |
Oct, 2027
(3 years from now) | |
Market Authorisation Date: 20 December, 2018
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
ELEPSIA XR family patents
2. Keppra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8802142 | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Jun, 2031
(7 years from now) | |
|
US8802142 (Pediatric) | UCB INC | Pharmaceutical compositions comprising levetiracetam and process for their preparation |
Dec, 2031
(8 years from now) | |
Market Authorisation Date: 30 November, 1999
Treatment: NA
Dosage: TABLET;ORAL
KEPPRA family patents
3. Keppra Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7858122 | UCB INC | Extended release formulation of levetiracetam |
Sep, 2028
(4 years from now) | |
Market Authorisation Date: 12 September, 2008
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
KEPPRA XR family patents
4. Spritam patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9339489 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(10 years from now) | |
| US9669009 | APRECIA PHARMS | Rapid disperse dosage form containing levetiracetam |
Mar, 2034
(10 years from now) | |
| US11160786 | APRECIA PHARMS | Rapid disperse dosage form |
Mar, 2034
(10 years from now) | |
Market Authorisation Date: 31 July, 2015
Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions; Method of administering levetiracetam under fed conditions
Dosage: TABLET, FOR SUSPENSION;ORAL
SPRITAM family patents